PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
PTC Therapeutics (NASDAQ: PTCT) announced that CEO Matthew B. Klein, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026 at 9:00 a.m. PST / 12:00 p.m. EST.
The presentation will be webcast live on the company’s Events and Presentations investor page at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – PTCT
In the Dec 18 session, PTCT declined 0.47%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Inducement grants | Neutral | -7.9% | New-hire inducement equity grants with options and RSUs under Nasdaq Rule 5635(c)(4). |
| Nov 20 | R&D day announcement | Positive | +1.1% | Scheduled R&D Day to showcase small molecule splicing and inflammation platforms. |
| Nov 04 | Q3 2025 earnings | Positive | -0.3% | Reported Q3 2025 revenue, positive net income and updated full-year guidance. |
| Oct 31 | Investor conferences | Neutral | +0.3% | Participation in multiple global healthcare investor conferences with webcasts. |
| Oct 27 | Inducement grants | Neutral | +0.6% | Inducement equity awards for new employees with four-year vesting terms. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent headlines (earnings, R&D and conference participation, inducement grants) have generally produced modest single-day moves, with one larger decline following an inducement grant announcement.
Over the last few months, PTC Therapeutics reported Q3 2025 results with $211.0M revenue and positive net income of $15.9M, alongside narrowed 2025 revenue guidance. The company highlighted launches and regulatory milestones for Sephience and other products. It has also frequently announced inducement equity grants and participation in multiple healthcare investor conferences. Today’s J.P. Morgan Healthcare Conference appearance continues this pattern of regular investor-focused communication and non-clinical corporate updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The presentation will be webcast live on the Events and Presentations page of the Investors section of the PTC Therapeutics website at https://ir.ptcbio.com/events-presentations, and it will be archived for 30 days following the presentation.
About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Facebook, and Instagram.
For More Information:
Investors:
Ellen Cavaleri
+1 (615) 618-6228
ecavaleri@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302645455.html
SOURCE PTC Therapeutics, Inc.